Advertisement

Topics

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 Pipeline Review, H1 2017

Summary

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 Leucinerich repeat kinase 2 LRRK2 is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor M6PR, between lysosomes and the Golgi apparatus in a retromerdependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 8 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Respiratory which include indications Parkinson's Disease, Neurodegenerative Diseases, Glaucoma and Lung Disease.

The latest report Leucine Rich Repeat SerineThreonine Protein Kinase 2 Pipeline Review, H1 2017, outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1
The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Dardarin or LRRK2 or EC 2.7.11.1 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...